Shire has grabbed a preliminary injunction in a Hamburg court against its rival Roche over emicizumab, its hemophilia drug. Shire alleges that Roche has released misleading statements over the drug.
According to Shire, the injuction is meant to help patients with hemophilia receive sufficient, accurate information about what Shire perceives to be Roche's under reporting of the adverse affects that were found in the Phase 3 emicizumab trial.
In June, Roche said that its drug reduced bleed rates by 87 percent in patients with resistance to standard therapy, while analysts found adverse events that included blood vessel damage in vital organs.
The injunction is an interim measure that Roche can still appeal.
Read the Reuters report